Abstract:Objective To study the role of Med19 in bladder cancer by analyzing the effects of lentivirus-mediated suppression of Med19 expression on T24 bladder cancer cells in vitro.Methods The lentivirus vectors containing a small hairpin RNA (shRNA) to target Med19 were constructed.After T24 bladder cancer cells were infected,real-time PCR and Western-blotting were used to study the Med19 expressions in the CON group (non-infected cells),the NC group (Lv-NC-infected cells) and the KD group (Lv-shMed19-infected cells).The influence of Med19 on the proliferation of bladder cancer cells were assessed using MTT,BrdU,colony formation assay and tumorigenicity experiment in mice.Cell cycle was analyzed with flow cytometry assay.Results Med19 relative mRNA level (0.35 ± 0.03) and Med19 protein expressing in the KD group were significantly inhibited (P ＜ 0.05).The KD group displayed an increased proportion of cells (77.50 ± 0.29)％ in the G0/G1 phase compared with the CON group (69.81 ± 0.81)％and NC group (67.53 ± 0.67) ％ (P ＜ 0.05).Compared with the CON group and the NC group,the KD group displayed a significant cell proliferation defect by MTT and BrdU assay and the number of colonies (91.33 ± 6.11) was significant decreased (P ＜ 0.05).On the day 24,the tumor volume (596.64 ± 485.36) mm3 and weight (0.57 ± 0.44) g of the KD group mice were decreased after inoculation into nude mice (P ＜ 0.05).Specific lentivirus-mediated knockdown of Med19 significantly impacted the cell cycle and proliferation of bladder cancer cells.Infected T24 cells nearly lost their tumorigenicity when being inoculated into nude mice.Conclusion Our results provide new evidence of an important role for Med19 in the development of bladder cancer,suggesting that lentiviruses delivering shRNA against Med19 may be a promising tool for bladder cancer therapy.

MED19 Promotes Proliferation and Tumorigenesis of Lung Cancer

Knockdown of Med19 suppresses proliferation and enhances chemo-sensitivity to cisplatin in non-small cell lung cancer cells.

The Role of Med19 in the Proliferation and Tumorigenesis of Human Hepatocellular Carcinoma Cells.

Expression of Med19 in bladder cancer tissues and its role on bladder cancer cell growth.

Role of Med19 in the Proliferation and Tumorigenicity of Human Bladder Cancer Cells

Mediator Complex Subunit 19 Promotes the Development of Hepatocellular Carcinoma by Regulating the AKT/mTOR Signaling Pathway

Knockdown of Med19 Enhances Chemo-sensitivity to Cisplatin in NSCLC Cells

Med19 is targeted by miR-101-3p/miR-422a and promotes breast cancer progression by regulating the EGFR/MEK/ERK signaling pathway.

Correlation of Long Non-Coding Rna H19 Expression with Cisplatin-Resistance and Clinical Outcome in Lung Adenocarcinoma

LncRNA H19 promotes lung cancer proliferation and metastasis by inhibiting miR-200a function

Knockdown of mediator complex subunit 19 inhibits the growth of ovarian cancer.

MicroRNA-19 Triggers Epithelial–mesenchymal Transition of Lung Cancer Cells Accompanied by Growth Inhibition

Knockdown Of Med19 By Lentivirus-Mediated Shrna In Human Osteosarcoma Cells Inhibits Cell Proliferation By Inducing Cell Cycle Arrest In The G(0)/G(1) Phase

H19-Derived Mir-675 Functions As An Oncogenic Microrna In Human Colorectal Cancers Through Targeting The Rb Tumor Suppressor

H19 promotes aerobic glycolysis, proliferation, and immune escape of gastric cancer cells through the microRNA-519d-3p/lactate dehydrogenase A axis

MicroRNA-19a Promotes Proliferative and Migratory Abilities of NSCLC Cells by Inhibiting PTEN Expression

C-Myc-regulated Long Non-Coding RNA H19 Indicates a Poor Prognosis and Affects Cell Proliferation in Non-Small-cell Lung Cancer

Targeting H19 by lentivirus-mediated RNA interference increases A549 cell migration and invasion

Long non‐coding RNA H19 is responsible for the progression of lung adenocarcinoma by mediating methylation‐dependent repression of CDH1 promoter

Mediator of RNA Polymerase II Transcription Subunit 19 Promotes Osteosarcoma Growth and Metastasis and Associates with Prognosis

H19 promotes non-small-cell lung cancer (NSCLC) development through STAT3 signaling via sponging miR-17